Skin Toxicity Caused by EGFR Antagonists: An Autoinflammatory Condition Triggered by Deregulated IL-1 Signaling?

The document discussed the skin toxicity associated with the use of EGFR inhibitors in cancer treatment, which often manifested as a papulopustular rash similar to acne. The study proposed that this skin toxicity was linked to deregulated IL-1 signaling in keratinocytes of the hair follicle's outer root sheath. EGFR activation typically inhibited IL-1-dependent signaling, but its blockade could enhance this signaling, leading to inflammation. The study highlighted the potential of targeting IL-1 signaling to manage this side effect, suggesting agents like Anakinra, an IL-1 receptor antagonist, as possible treatments. The document also emphasized the need for suitable animal models to test these therapeutic strategies effectively.